Management & Directors
Johanna Holldack (Chairman)
Dr. Holldack has worked in the pharmaceutical industry for more than 20 years, where she has held key positions in both start-up and large pharma companies. Her experience includes management and executive positions at Behringwerke, Chiron, MediGene, Borean Pharma and Telormedix. She is currently CEO of Trethera.
Dr. Holldack has a medical degree from Georg-August-University in Gottingen, Germany and is a Board Certified pediatrician. In addition, she has held positions as an assistant professor at the University of Essen, research fellow for the Deutsche Krebshilfe and a research associate at Harvard Medical School.
Madiha Derouazi (Founder and CEO)
Madiha Derouazi has been working on vector engineering and therapeutic cancer vaccines for over 10 years. She has a strong background in applied molecular and cellular biotechnology, with research interests at the interface of fundamental and translational research, the so called bench-to-bedside. After several years working on recombinant protein production (upstream), she started developing different antigen delivery vectors. In the Laboratory of Tumor Immunology of the University of Geneva, she designed and characterized the CPP-based multi-epitopic cancer vaccine that is currently being progressed by Amal Therapeutics. Madiha Derouazi holds a PhD in Biotechnology from the Ecole Polytechnique Fédérale de Lausanne (EPFL), Switzerland and a Master in Biotechnology Engineering from the University of Technology of Berlin, Germany.
Hanna Kleczkowska (Director)
Hanna Kleczkowska is the Principal Investment Advisor at Helsinn International Services (HIS), an advisory body to the Helsinn Investment Fund. Before joining HIS, Hanna worked for Helsinn Healthcare in the Business Development function, leading a team focusing on new product evaluations for in-licensing or acquisition. Prior to Helsinn, Hanna held senior management positions at Bank Julius Baer and UBS, where she had been involved in private and public equity transactions. Hanna started her career at the University of Zurich where she did independent research on the molecular mechanisms of cancer. Later on, at the Ludwig Institute for Cancer Research, she coordinated a cancer biomarker database project.
Hanna holds a Ph.D. in Molecular Biology from University of Warsaw
Knut Elbers (Director)
Knut is Director of the Boehringer Ingelheim Corporate Venture Fund. Over the last three years, he has been involved in several investments of the fund. He served as board member of Okarios AG in Basel having had a successful exit in 2013. He is also board member of NBE Therapeutics in Basel since 2013. His scientific strength especially in the field of immunotherapy and NBE technologies is resulting in strategic input in the Venture Fund strategy in this specific focus space.
Knut joined Boehringer Ingelheim in 1995 in the international research and development department of the animal health business. From 1999 to 2008 he was heading the European vaccine research organization for animal health. Subsequently he collected experiences in human antibody related research and development being involved in R&D project management and Collaborative Research for NBEs. During his work at Boehringer Ingelheim Knut was involved in 12 patent applications and key development projects (Ingelvac PRRSV, Enterisol Ileitis, Ingelvac CircoFLEX) contributing significantly to the vaccine business success of the animal health business of Boehringer Ingelheim. Knut has studied biology at the Eberhard-Karls-University in Tübingen with specific focus on virology and immunology. He performed his Ph.D. work at the federal institute for viral diseases in Tübingen focusing on protein processing during viral replication and pathogen/host interaction mechanism.
Diego Braguglia (Director)
Diego Braguglia has over 20 years of experience in life science, medical devices and pharmaceuticals in Europe and the US. Prior to his entry as General Partner for VI Partners, he has held various managerial positions in the pharmaceuticals and medical devices sectors. In addition to its role in Amal Therapeutics board, Diego presently represents VI Partners in various biotech start-ups companies.
Diego holds a M.Sc. in Microbiology from the Biocenter of the University of Basel and a Ph.D. in Molecular and Cellular Biology from the Swiss Cancer Research Institute (ISREC) in Lausanne.
Andreas Wallnöfer (Director)
Dr. Wallnöfer joined BioMedPartners as a new Partner in 2016. Dr. Wallnöfer is a senior executive leader with more than 20 years experience in the pharmaceutical industry, including 12 years as a member of the F. Hoffmann-La Roche Pharma R&D Leadership and Portfolio Committee. He led the Roche Pharma Cardiovascular & Metabolism Disease Area and left Roche in 2015 after the company strategically decided to exit these reasearch areas.
At Roche he was involved in several successful product development programs. As Head of Clinical Research & Exploratory Development he and his groups were involved in the Due Diligence evaluations for in-licensing projects and product acquisitions. Dr. Wallnöfer had also a key role in the integration of the Roche and Genentech Development organizations and led subsequently Early Development and Portfolio Management at Roche. He will strengthen BioMed expertise in Pharma from discovery to regulatory filing submissions.
Dr. Wallnöfer has a PhD in pharmacology from the University of Basel and trained as a fellow in Clinical Pharmacology at the University of Leiden, the Netherlands. He holds a Master of Technology Enterprise and an Executive MBA from IMD Lausanne.